Understanding how the immune system controls tuberculosis
The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis From Healthy Blood Donors and Patients With Latent or Active Tuberculosis.
This study is testing how well the immune system controls tuberculosis by comparing blood samples from healthy people and those with different stages of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 280 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Linkoeping University Government |
| Locations | 2 sites (Kalmar and 1 other locations) |
| Trial ID | NCT06580639 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the immune response to Mycobacterium tuberculosis (M. tuberculosis) by comparing blood samples from healthy individuals, patients with latent tuberculosis, and those with active tuberculosis. The study will utilize a Mycobacterial Growth Inhibition Assay (MGIA) to quantify how effectively blood leucocytes can suppress the growth of M. tuberculosis. By analyzing differences in immune control among these groups, the research seeks to enhance understanding of host immunity against tuberculosis. Participants will be recruited from departments of infectious diseases in specific regions of Sweden.
Who should consider this trial
Good fit: Ideal candidates include healthy blood donors, individuals recently exposed to tuberculosis, and patients with latent or active tuberculosis.
Not a fit: Patients with known HIV infection or other forms of immunosuppression will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of tuberculosis immunity, potentially guiding better prevention and treatment strategies.
How similar studies have performed: While the MGIA method has been previously developed, this specific application in a diverse patient population is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Healthy blood donors or subjects who will get vaccinated. Exclusion Criteria:Known HIV infection, not Swedish citizen, chronic liver och kidney disease,immunosuppression from treatment or disease.
Where this trial is running
Kalmar and 1 other locations
- Kalmar County Hospital — Kalmar, Sweden (Recruiting)
- Dept of Infectious Diseases — Linköping, Sweden (Recruiting)
Study contacts
- Principal investigator: Thomas Schoen, Professor — Linkoeping University
- Study coordinator: Thomas Schoen, Professor
- Email: tschon@hotmail.com
- Phone: +48013580000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.